AVITA Medical, Inc. (RCEL)
Market Cap | 241.13M |
Revenue (ttm) | 51.57M |
Net Income (ttm) | -35.38M |
Shares Out | 25.71M |
EPS (ttm) | -0.90 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 223,325 |
Open | 9.81 |
Previous Close | 9.70 |
Day's Range | 9.34 - 9.88 |
52-Week Range | 9.16 - 21.70 |
Beta | 1.29 |
Analysts | Strong Buy |
Price Target | 28.25 (+201.17%) |
Earnings Date | May 13, 2024 |
About RCEL
AVITA Medical, Inc., together with its subsidiaries, operates as a regenerative medicine company in the United States and internationally. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds, full-thickness skin defects, and repigmentation of stable depigmented vitiligo lesions. It develops RECELL GO to control the manual process of disaggregation, filtration, and soak time. The company was formerly known as AVITA Therapeutics, Inc. AVITA Medical, Inc. was incorporated in 2020 ... [Read more]
Financial Performance
In 2023, AVITA Medical's revenue was 51.57 million, an increase of 37.03% compared to the previous year's 37.64 million. Losses were -35.38 million, 32.7% more than in 2022.
Financial numbers in AUD Financial StatementsAnalyst Forecast
According to 5 analysts, the average rating for RCEL stock is "Strong Buy." The 12-month stock price forecast is $28.25, which is an increase of 201.17% from the latest price.
News
AVITA Medical to Announce First Quarter 2024 Financial Results
AVITA Medical will report first quarter 2024 financial results after the close on May 13, 2024, and host a webcast that day at 1:30 p.m. Pacific Time.
AVITA Medical Updates Expected First Quarter 2024 Revenue
AVITA Medical updates expected Q1 2024 commercial revenue; reaffirms expectations for full-year 2024 revenue at lower end of previously provided guidance.
AVITA Medical Submits Response to FDA, Resuming Review Clock for RECELL GO PMA Supplement
AVITA Medical submitted its response to FDA for additional information in connection to RECELL GO PMA supplement. Submission resumes substantive review.
AVITA Medical to Present at TD Cowen 44th Annual Health Care Conference
VALENCIA, Calif., Feb. 29, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care mana...
AVITA Medical to Host Investor Webinar Briefing
VALENCIA, Calif., Feb. 23, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care mana...
AVITA Medical Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides 2024 Financial Guidance
VALENCIA, Calif., Feb. 22, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care mana...
AVITA Medical to Announce Fourth Quarter and Full Year 2023 Financial Results
VALENCIA, Calif., Feb. 01, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices and autologous cell...
AVITA Medical Announces Exclusive Distribution Agreement with Stedical Scientific
VALENCIA, Calif., Jan. 10, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (the “Company”), a commercial-stage regenerative medicine company focused on first-in-class devices and...
AVITA Medical Announces Preliminary 2023 Financial Highlights, Provides 2024 Financial Guidance and Business Update
VALENCIA, Calif., Jan. 10, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (the “Company”), a commercial-stage regenerative medicine company focused on first-in-class devices and...
AVITA Medical to Present at the 42nd Annual J.P. Morgan Healthcare Conference
VALENCIA, Calif., Jan. 04, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices and autologous cell...
AVITA Medical to Present at the Piper Sandler 35th Annual Healthcare Conference
VALENCIA, Calif., Nov. 21, 2023 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (the “Company”), a regenerative medicine company leading the development and commercialization of first...
AVITA Medical Updates Full Year 2023 Guidance
VALENCIA, Calif., Nov. 20, 2023 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (the “Company”), a regenerative medicine company leading the development and commercialization of first...
AVITA Medical Reports Third Quarter Financial Results with 51% Revenue Growth over the Same Period the Prior Year
VALENCIA, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (the “Company”), a regenerative medicine company leading the development and commercialization of first...
AVITA Medical Announces Distribution Partnership with PolyMedics Innovations to Expand to Europe
AVITA Medical announced it has entered into a distribution agreement with PolyMedics Innovations, to strategically expand its global presence to Europe.
AVITA Medical to Announce Third Quarter 2023 Financial Results
VALENCIA, Calif., Oct. 19, 2023 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company leading the development and commercialization of first-in-class device...
AVITA Medical Receives Best Product Award at the American Association for the Surgery of Trauma
VALENCIA, Calif., Sept. 25, 2023 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company leading the development and commercialization of first-in-class devic...
AVITA Medical to Present at the Cantor Global Healthcare Conference
VALENCIA, Calif., Sept. 21, 2023 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company leading the development and commercialization of first-in-class devic...
AVITA Medical to Participate in Upcoming Investor Conferences
VALENCIA, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company leading the development and commercialization of first-in-class devic...
AVITA Medical Reports Second Quarter Financial Results
VALENCIA, Calif., Aug. 10, 2023 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (the “Company”), a regenerative medicine company leading the development and commercialization of first...
AVITA Medical Submits FDA PMA Supplement for RECELL GO
VALENCIA, Calif., June 29, 2023 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company leading the development and commercialization of first-in-class device...
AVITA Medical Announces FDA Approval of RECELL for Skin Repigmentation in Vitiligo Patients
VALENCIA, Calif. and MELBOURNE, Australia, June 16, 2023 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company leading the development and commercialization...
AVITA Medical Announces Appointment of David O'Toole as Chief Financial Officer
VALENCIA, Calif. and MELBOURNE, Australia, June 15, 2023 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company leading the development and commercialization...
AVITA Medical Announces FDA Approval of RECELL for Treatment of Full-Thickness Skin Defects
VALENCIA, Calif. and MELBOURNE, Australia, June 07, 2023 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company leading the development and commercialization...
AVITA Medical Reports First Quarter Financial Results and Affirms Full Year Guidance
VALENCIA, Calif. and MELBOURNE, Australia, May 11, 2023 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (the “Company”), a regenerative medicine company leading the development and co...
AVITA Medical to Announce First Quarter 2023 Financial Results
VALENCIA, Calif. and MELBOURNE, Australia, April 20, 2023 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company leading the development and commercializatio...